Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 7(1): 15480, 2017 11 13.
Article in English | MEDLINE | ID: mdl-29133816

ABSTRACT

We have devised an effective and robust method for the characterization of gene-editing events. The efficacy of editing-mediated mono- and bi-allelic gene inactivation and integration events is quantified based on colony counts. The combination of diphtheria toxin (DT) and puromycin (PM) selection enables analyses of 10,000-100,000 individual cells, assessing hundreds of clones with inactivated genes per experiment. Mono- and bi-allelic gene inactivation is differentiated by DT resistance, which occurs only upon bi-allelic inactivation. PM resistance indicates integration. The robustness and generalizability of the method were demonstrated by quantifying the frequency of gene inactivation and cassette integration under different editing approaches: CRISPR/Cas9-mediated complete inactivation was ~30-50-fold more frequent than cassette integration. Mono-allelic inactivation without integration occurred >100-fold more frequently than integration. Assessment of gRNA length confirmed 20mers to be most effective length for inactivation, while 16-18mers provided the highest overall integration efficacy. The overall efficacy was ~2-fold higher for CRISPR/Cas9 than for zinc-finger nuclease and was significantly increased upon modulation of non-homologous end joining or homology-directed repair. The frequencies and ratios of editing events were similar for two different DPH genes (independent of the target sequence or chromosomal location), which indicates that the optimization parameters identified with this method can be generalized.


Subject(s)
CRISPR-Cas Systems/genetics , Gene Editing/methods , Minor Histocompatibility Antigens/genetics , Proteins/genetics , Tumor Suppressor Proteins/genetics , Alleles , Diphtheria Toxin/administration & dosage , Gene Knockout Techniques/methods , Genetic Vectors/genetics , Histidine/analogs & derivatives , Histidine/biosynthesis , Humans , MCF-7 Cells , Minor Histocompatibility Antigens/metabolism , Proteins/metabolism , Puromycin/administration & dosage , Transfection/methods , Transgenes/genetics , Tumor Suppressor Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...